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Dietary fatty acids and the glomerular hemodynamic response to
cyclosporine in borderline hypertensive rats. We have recently reported
that cyclosporine A (CsA) decreases glomerular filtration rate in the
borderline hypertensive rat (BHR), but that the glomerular filtration rate
is normal when the rats are maintained on a diet supplemented with
evening primrose (EP) oil. The current studies were designed to deter-
mine the glomerular hemodynamic changes responsible for this effect. A
first group (PLAC-SAFF) received a diet supplemented with safflower oil
(SAFF) (10% of calories) and placebo (PLAC). A second group (CsA-
SAFF) received a diet supplemented with SAFF and CsA (10 mg/kg/day).
A third group (CsA-EP) also received CsA, but the diet was supplemented
with EP oil (10% of calories). Routine micropuncture studies were
performed after five to nine weeks of treatment. Single nephron glomer-
ular filtration rate (SNGFR) was lower in CsA-SAFF than in PLAC-SAFF
(36 2 vs. 46 1 nI/mm, p < 0.05). Maintenance of SNGFR in CsA-EP
compared to CsA-SAFF (48 2 nI/mm vs. 36 2 nI/mm, P < 0.05) was
due to higher values for single nephron plasma flow rate (156 16 vs. 118
9 nl/min, P < 0.05), and higher values for the glomerular capillary
ultrafiltration coefficient (0.09 1 0.013 vs. 0.054 0.010 nl/s/mm Hg, P <
0.05). Since dietary fatty acids can affect prostaglandmn (PG) production,
we measured PGE production in isolated glomeruli. Mean values for basal
production rates of PGE were greater in rats maintained on EP than in
rats maintained on SAFF (3958 105 vs. 3378 146 pg PGE/mg
glomerular protein, P < 0.05). Increased renal vasodilatory PG production
may be responsible, at least in part, for the maintenance of normal
SNGFR in CsA-EP rats.
Cyclosporine A (CsA) improves allograft survival in transplant
recipients, but treatment is complicated by acute and chronic
nephrotoxity [1—4]. Early impairment of glomerular filtration rate
is due to an increase in renal vascular resistance which reduces
renal plasma flow [5—8], although the mechanisms responsible for
impairment of glomerular filtration rate have not been fully
elucidated. We have recently reported that CsA treatment lowers
glomerular filtration rate and increases awake systolic blood
pressure in borderline hypertensive rats (BHR) when the dose of
cyclosporine is limited to 10 mg/kg/day, and CsA trough levels
average 223 36 ng/ml [9]. We also observed that dietary
supplementation with evening primrose (EP) oil prevented the
decline glomerular filtration rate in CsA-treated BHR [9].
Accordingly, the first aim of the current study was to determine
the glomerular hemodynamic changes responsible for mainte-
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nance of normal glomerular filtration in CsA-treated BHR main-
tained on EP oil. A second aim was to determine whether dietary
supplementation with EP reduced incorporation of CsA into renal
tissue. Since EP oil contains significant amounts of gamma
linolenic acid (GLA), a metabolic precursor of arachidonic acid
[10—14], and diets rich in GLA can increase tissue prostaglandin
E (PGE) production [11, 14], the final aim of the current study




Male BHR were utilized in all of the experimental protocols.
The animals were bred at the University of Waterloo, Waterloo,
Ontario, Canada.
Micropuncture studies
For the micropuncture studies, BHR were randomly assigned
to three diet and CsA treatment groups, five weeks after weaning.
A first group (PLAC-SAFF) received 0.10 ml of placebo daily by
oral gavage (Sandimmune Placebo, Sandoz, Canada) and Purina
rat chow supplemented with safflower oil (SAFF) (10% of total
calories), containing 79% linoleic acid. A second group (CsA-
SAFF) received CsA (Sandoz) administered by oral gavage at a
dose of 10 mg/kg/day in 0.10 ml of olive oil and Purina rat chow
supplemented with safflower oil. A third group (CsA-EP) received
CsA (Sandoz) administered by oral gavage at a dose of 10
mg/kg/day in 0.10 ml of olive oil and Purina rat chow supple-
mented with evening primrose oil (EP) (10% of total calories),
(Efamol Ltd, Kentville, Nova Scotia, Canada), containing 72%
linoleic acid and 9% gamma linolenic acid. By design, every
animal received 20 grams of chow per day, an amount that was
entirely consumed by the rats in all three groups. Studies were
performed five to nine weeks after dietary and treatment assign-
ment.
Six animals from each group underwent routine micropuncture
study. Rats were anesthetized with mactin, 100 mg/kg intraperi-
toneally, and placed on a temperature-regulated micropuncture
table. A PE-50 tubing was inserted into the left femoral artery and
used to monitor mean arterial pressure (MAP), and to obtain
arterial blood samples. MAP was monitored continuously with an
electronic transducer connected to a dual channel direct writing
recorder.
After tracheostomy, PE-50 catheters were introduced into the
right and left internal jugular veins for infusion of rat plasma,
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saline, and inulin, A PE-lO catheter was inserted into the left
ureter. After insertion of the jugular catheters, 1% body weight
plasma was infused over 35 to 45 minutes, followed by a plasma
infusion of approximately 0.50 ml/hr [151. Saline was infused at a
rate of 2.0 mi/hr and served as the vehicle for 3H-inulin (NEN). A
loading dose of —-60 MC of 3H-inulin was administered and
followed by an infusion rate of —90 MC/hr [16, 17].
Micropuncture measurements were carried out over 60-minute
clearance periods. At the midpoint of each period, a 200 jl
arterial blood sample was obtained for determination of hemat-
ocrit, plasma inulin, and plasma protein concentrations. A renal
vein blood sample was obtained with each arterial blood sample to
determine filtration fraction (FF) by comparison of arterial and
renal vein inulin concentrations. A continuous recording servo-
null micropipette transducer system (Model V, Instrumentation
for Physiology and Medicine, San Diego, CA, USA) was used to
obtain time-averaged hydraulic pressures in surface proximal
tubules after blockade with an oil droplet (3 to 4 measures per
animal), free-flowing proximal tubules (four measures per animal)
and efferent arterioles (2 to 3 measures per animal). Hydraulic
output from the servo-null system was transmitted to the second
channel of the direct writing recorder by means of a pressure
transducer. Timed (4 mm) samples of tubule fluid were collected
from the surface convolutions of two to three nephrons for
determination of single nephron glomerular filtration rate.
Clearance studies and tissue levels of CsA
BHR were randomly assigned to two groups, five weeks after
weaning. A first group (PLAC-SAFF) received Purina rat chow
supplemented with safflower oil (to 10% of total calories) and 0.10
ml of placebo daily by oral gavage (Sandimmune Placebo, Sandoz,
Canada). A second group (PLAC-EP) received Purina rat chow
supplemented with evening primrose oil (to 10% of total calories)
and 0.10 ml of placebo daily by oral gavage. By design, every
animal received 20 grams of chow per day. Studies were per-
formed five weeks after treatment and dietary assignment.
Four rats each group were anesthetized with mactin, 100 mg/kg
intraperitoneally, and prepared for study as above. After insertion
of the jugular catheters, 1% body weight plasma was infused over
35 to 45 minutes, followed by a plasma infusion of approximately
0.50 mi/hr [151. Saline was infused at a rate of 2.0 ml/hr and served
as the vehicle for 3H-inulin. A loading dose of —20 MC of
3H-inulin was administered and followed by an infusion rate of
-—30 MC/hr [16, 17]. Clearance measurements were carried out
over two 30-minute collection periods. At the midpoint of each
period, a 200 p1 arterial blood sample was obtained for determi-
nation of hematocrit, plasma inulin, and plasma protein concen-
trations.
Five animals from each group received 42 mg/kg of 3H-CsA by
gastric lavage. Seven hours after administration of 3H-CsA, the
animals were subjected to halothane anesthesia. The liver and
kidneys were flushed with normal saline in situ to remove blood,
then dissected free, weighed, and added to BTS 450 tissue
solubilizer (Beckman, Palo Alto, California) for 24 hours at 50°C.
The incorporation of 3H-CsA, including parent compound and
metabolites, into liver and kidney tissue was determined by liquid
phase scintillation counting. Measures were normalized per gram
of wet tissue.
Measurement of glomerular eicosanoid production
For the determination of glomerular PGE production, BHR
were randomly assigned to four groups, five weeks after weaning.
A first group (PLAC-SAFF) received 0.10 ml of placebo daily by
oral gavage and Purina rat chow supplemented with safflower oil.
A second group (CsA-SAFF) received CsA (Sandoz) by oral
gavage, at a dose of 10 mg/kg/day in 0.10 ml of olive oil, and
Purina rat chow supplemented with safflower oil. A third group
(PLAC-EP) received 0.10 ml of placebo daily by oral gavage and
Purina rat chow supplemented with evening primrose oil. A fourth
group (CsA-EP) received CsA by oral gavage, at a dose of 10
mg/kg/day in 0.10 ml of olive oil, and Purina rat chow supple-
mented with evening primrose oil. By design, every animal
received 20 grams of chow per day, and studies were performed
five weeks after treatment and dietary assignment.
Six animals from each group were anesthetized with Brietal, 50
mg/kg intraperitoneally, and glomeruli were isolated for determi-
nation of eicosanoid production rates [18]. The kidneys were
perfused with 50 mis of ice-cold, heparinized normal saline (0.9%)
and two kidneys from a single rat were pooled for isolation of
glomeruli. Renal cortical tissue was dissected from the medulla,
minced, and passed through 106 m and 75 m sieves so that the
glomeruli collected on the 75 m sieve, Aliquots of each sample
were visualized directly on a microscope stage and there were
fewer than 10 tubular elements per 100 glomeruli. The glomeruli
were rinsed off of the sieve and re-suspended in ice-cold 20 mM
Tris buffer containing 135 mtvi NaC1, 10 mrvi NaCOOH, and 5 mM
glucose (pH 7.4). The suspension was centrifuged at 1200 g for
two minutes and the supernatant was discarded. The pellet was
re-suspended in ice-cold Tris buffer, and then centrifuged again
for two minutes. The pellet was resuspended in 2 ml of 20 mM Tris
buffer with 135 m'vi NaC1, 10 mrvi NaCOOH, 5 mi glucose, and 1
mM CaCl. Five hundred microliter aliquots were incubated for 30
minutes at 37°C in a water bath shaker. Reactions were stopped by
immersion in ice. Following centrifugation at 22,000 g at 4°C for
two minutes, the supernatant was collected and stored at —20°C.
The pellet was then resuspended in 500 Ml of normal saline, and
the total protein concentration was assayed by the Lowry method
[19]. PGE was measured directly by radioimmunoassay utilizing
commercially available 3H-PGE2 (Sigma Chemical Co., St. Louis,
MO, USA) and rabbit PGE2 antiserum (Product #P-5164, Sig-
ma). The antiserum cross reacts with PGE1.
Analytical
Protein concentration of arterial plasma (CA) was determined
by refractometry. Glomerular protein was measured by the
method of Lowry et al [19]. 3H-inulin content of plasma, urine,
and tubule fluid was assessed by liquid-phase scintillation count-
ing (Beckman LS17O1). 3H-CsA content of whole blood, kidney
tissue, and liver tissue was assessed by liquid-phase scintillation
counting.
Calculations and statistics
Efferent arteriolar plasma protein concentration (Cs) was
estimated from the relation:
CA
CE 1-FF
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PLAC-SAFF 378±11 138±8 45±2 46±1 0.35±0.02
CsA-SAFF 370±14 134±7 43±1 36±2" 0.31±0.02




CA C 7A E
gIdI mm Hg
PLAC-SAFF 133±7 5.2±0.1 8.0±0.4 16±1 32±2
CsA-SAFF 118±9 5.5±0.1 8.0±0.3 18±1 33±2
CsA-BP 156 16 5.2±0.2 7.7 03 17 1 30 1
Group
PGC A' 1E R
1010 dynesec cmmm Hg
PLAC-SAFF 49±1 12±1 37±1 15 1 2.96±0.43
CsA-SAFF 50±2 11 1 38±2 15 1 3.43
CsA-EP 45 12±1 33 15 1 155±0.30
Group
RT K,
n/sec/mm Hg1010 dyne sec. cm
PLAC-SAFF 1.38 0.09 4.34 0.50 0.067 0.011
CsA-SAFF 1.74 0.21 5.17 0.56 0.054 0.010
CsA-EP 1.11 o.14a 3.66 0.4P 0.091 0.013k'
Values are mean SE. Abbreviations are: N, number of rats; Hct, hematocrit; MAP, mean arterial pressure; SNGFR, single nephron glomerular
filtration rate; FF, filtration fraction; QA, glomerular plasma flow rate; P0, mean glomerular capillary hydraulic pressure; T, proximal tubule hydraulic
pressure; P, mean glomerular transcapillary hydraulic pressure difference; F, efferent arteriolar hydraulic pressure; CA and CE, afferent and efferent
arteriolar plasma protein concentration, respectively; IrA and IrE, afferent and efferent arteriolar colloid osmotic pressure, respectively; RA and R,
afferent and efferent arteriolar resistance, respectively; RT, total arteriolar resistance (Ra+Re); Kf, glomerular capillary ultrafiltration coefficient.
P C 0.05 CsA-EP vs. CsA-SAFF
"P C 0.05 CsA-SAFF vs. PLAC-SAFF
cp < 0.05 CsA-EP vs. PLAC-SAFF
Oncotic pressure (ir) of efferent and afferent arteriolar plasma
was estimated from the total protein concentration (C) as:
ii = 1.629 C + 0.294 C2
The glomerular capillary pressure (P0) was estimated from the
mean stop flow pressure (sF) and the oncotic pressure of arterial
plasma (IrA) from the relation:
GC = SF + IrA
A standard mathematical model was used to derive the glomeru-
lar capillary ultrafiltration coefficient (KE) and single afferent and
efferent arteriolar resistances from values for oncotic pressure,
glomerular capillary pressure, and from measured parameters
[20].
The statistical significance of differences among values of
individual parameters was evaluated by analysis of variance
(ANOVA) or an unpaired Student's t-test. Following ANOVA,
Fisher PLSD was used to assess the significance of differences
between individual group means. Significance was defined as P C
0.05. Values are expressed as mean standard error.
Results
Micropuncture studies
Mean values for body weight, hematocrit, mean arterial pres-
sure under anesthesia, SNGFR, and pressures, flows, and resis-
tances governing glomerular ultrafiltration for PLAC-SAFF, CsA-
SAFF, and CsA-EP rats are summarized in Table 1. Values for
body weight were similar in the three groups at the time of study.
Values for hematocrit were lower in group CsA-EP than in
PLAC-SAFF rats (42 1 vs. 45 2, P C 0.05). Dietary
assignment and CsA treatment had no effect on mean arterial
pressure (MAP) under anesthesia, in accord with our previous
observations [9].
Mean values for SNGFR averaged 46 2 nI/mm in PLAC-
SAFF, 36 2 nl/min in CsA-SAFF, and 48 2 nl/min in CsA-EP.
The mean values for SNGFR were lower in CsA-SAFF rats than
in PLAC-SAFF rats (P C 0.05), and values for SNGFR normal-
ized in CsA-EP rats. Mean values for filtration fraction (FF) were
similar in the three groups.
Mean values for glomerular capillary hydrostatic pressure,
were lower in CsA-EP than in CsA-SAFF rats (45 2 mm
Hg vs. 50 2 mm Hg, P C 0.05), but values for proximal tubule
hydraulic pressure (PT), and efferent arteriolar hydraulic pressure
(Ps) were similar in all three groups. The glomerular transcapil-
lary hydraulic pressure gradient (AP) averaged 37 1 mm Hg in
PLAC-SAFF rats. In parallel with the measures of P0c, mean
values for AP were lower in CsA-EP rats than in CsA-SAFF rats
(33 2 mm Hg vs. 38 2 mm Hg, P C 0.05). Since values for
filtration fraction were not different, mean values for single
nephron plasma flow rate (QA) closely paralleled values for
SNGFR, and the difference in SNGFR between CsA-SAFF and
CsA-EP rats was due in part to the difference in °A (118 9





Fig. 1. Effect of dieta,y fatty acid supplementation on kidney and liver
incorporation of 3H-CYA (pg CsA/g tissue) following a single oral dose of
GsA. Mean values 7 hours after administration of CsA were similar in
PLAC-SAFF rats (U) and PLAC-EP ( ) rats. Dietary supplementation
with EP did not reduce incorporation of 3H-CYA (parent compound and
metabolites) into liver or kidney tissue of BHR. Values are mean
standard error.
arteriolar protein concentration, CA, and afferent arteriolar on-
cotic pressure, A' were similar in the three groups. The value
derived for the glomerular capillary ultrafiltration coefficient (l(f)
was significantly greater in CsA-EP rats than in CsA-SAFF rats
(0.091 .013 vs. 0.054 .010 nI/s/mm Hg, P < 0.05), thus
offsetting the decline in zP in CsA-EP rats.
The tendency for GC and zP to be lower in CsA-EP rats
compared to CsA-SAFF rats reflected a significant decrease in
efferent arteriolar resistance (RE) in group 3 (1.74 0.21 vs. 1.11
0.14 1010 dyne sec cm5, P < 0.05). Differences in afferent
arteriolar resistance among the three groups did not achieve
statistical significance. However, maintenance of plasma flow in
CsA-EP rats was due to a significant difference in total arteriolar
resistance (RT) compared to CsA-SAFF rats (3.66 0.41 vs. 5.17
0.56 1010 dyne sec cm5, P < 0.05).
Clearance studies
These studies were undertaken to determine whether dietary
supplementation with evening primrose oil increased GFR in
placebo-treated BHR. Mean values for body weight and hemat-
ocrit were similar in PLAC-SAFF and PLAC-EP rats (320 5 g
and 328 4 g; 46 1 and 45 1, respectively). MAP under
anesthesia was 135 4 mm Hg in PLAC-SAFF, and 132 3 mm
Hg in PLAC-EP. Whole kidney GFR was unchanged (1.60 0.25
vs. 1.52 0.18 mI/mm, P> 0.05).
Tissue levels of CsA
These studies were undertaken to determine whether the
dietary assignment to either SAFF or EP affected the tissue
incorporation of CsA in BHR. Mean values for the incorporation
of 3H-CsA into liver and kidney in SAFF and EP rats are depicted
in Figure 1. Whole kidney incorporation of 3H-CsA (including
parent compound and metabolites) was unchanged in SAFF rats
U
50)EE
Fig. 2. Effect of dietaiy fatty acids and CsA treatment on glomendar PGE
production (pg/mg glomerular protein/30 mm). There was a significant
increase in glomerular PGE production in rats maintained on EP com-
pared to rats maintained on SAFF. Values are mean SE. *P < 0.05 vs.
SAFF.
compared to EP rats (0.395 0.048 g CsA per g of kidney tissue
vs. 0.459 0.069 jg CsA per g of kidney tissue, P> 0.05).
Determination of glomerular eicosanoid production by
radioimmunoassay
Mean values for PGE production were similar in PLAC-SAFF
and CsA-SAFF rats (3234 133 vs. 3523 153 pg/mg of
glomerular protein/30 mm, P> 0.05), and mean values for PGE
production were similar in PLAC-EP and CsA-EP rats (3884
133 vs. 4032 153 pg/mg of glomerular protein per 30 mm
incubation, P > 0.05). There was a significant increase in PGE
production in PLAC-EP and CsA-EP rats compared to PLAC-
SAFF and CsA-SAFF rats (3958 105 vs. 3378 146 pg/mg of
glomerular protein per 30 mm incubation, P < 0.05), depicted in
Figure 2.
Discussion
The borderline hypertensive rat (BHR) is the first generation
cross between normotensive Wistar Kyoto rats and spontaneously
hypertensive rats (SHR). At maturity, the resting systolic blood
pressure is between 140 and 155 mm Hg in the BHR, but a variety
of stimuli, including dietary salt loading and environmental stress,
increase blood pressure to levels similar to that of the SHR [211.
In our initial report [9], we found that CsA treatment (10
mg/kg/day) was also a stimulus for the development of systolic
hypertension in the BHR. In addition, the glomerular filtration
rate declined. This combination of hemodynamic effects at non-
pharmacologic doses of CsA suggested that the CsA-treated BHR
was a good animal model of acute CsA nephrotoxicity, and was
the rationale for utilizing the BHR in the current study. We also
reported that values for GFR remained within the normal range
when CsA-treated BHR were maintained on a diet supplemented
with evening primrose (EP) oil [9]. Accordingly, the first aim of
the current study was to determine the glomerular hemodynamic
changes responsible for this preservation of GFR.
Mean values for SNGFR were significantly greater in CsA-EP
rats compared to CsA-SAFF rats because single nephron plasma
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I n-3 I
Fig. 3. Metabolism of n-6 and n-3 fatty acids.
Dietary linoleic acid [18:2(n-6)1 is desaturated
to gamma linolenic acid or GLA [18:3(n-6)]
and then elongated to dihomo gamma linolenic
acid or DGLA [20:3(n-6)]. A AS desaturase
converts DOLA to arachidonic acid [20:4(n-6)].
DGLA and arachidonic acid are metabolized to
the 1- and 2- series of prostanoids, respectively.
Evening primrose oil is enriched with GLA,
while safflower oil contains linoleie acid. Fish
oil concentrates contain n-3 fatty acids which
compete with arachidonie acid for
cyclooxygenase and lead to the production of
three series of prostanoids which have reduced
biological activity.
flow was greater and there was an increase in the glomerular
capillary ultrafiltration coefficient in the rats receiving a diet
supplemented with EP. The increase in °A reflected the signifi-
cant difference between total arteriolar resistance in CsA-EP rats
and CsA-SAFF rats. The micropuncture studies also revealed that
there was a greater effect on efferent arteriolar resistance than
afferent arteriolar resistance. As a consequence of this segmental
effect on intrarenal vascular resistance mean values for GC and
were lower in CsA-EP rats than in CsA-SAFF rats. The
resultant decrease in transcapillary hydraulic gradient, ISP, did not
lower SNGFR because the change in ultrafiltration pressure was
offset by an increase in the glomerular capillary ultrafiltration
coefficient, K1.
Of interest, values for K1 tended to be greater in CsA-EP rats
than in PLAC-SAFF rats, although the difference did not reach
statistical significance. The BHR is the first generation cross
between SHR and normotensive Wistar-Kyoto rats, and values for
K1 in SHR can also be increased by experimental maneuvers [22,
23]. Dworkin and coworkers showed that nifedipine treatment
increased IC to values that exceeded values derived for control
SHR rats, and they speculated that the ability to increase K1 in
SHR reflected increased intrarenal activity of vasoactive sub-
stances [24], For example, a decline in K in rats infused with
angiotensin II can be acutely reversed by calcium channel blockers
like verapamil [25]. In this regard, gamma linolenic acid (GLA)
has been shown to blunt the arterial pressor response to angio-
tensin II [26, 27], and such an effect may explain why the increase
in K1 and decrease in AP in CsA-EP resembles the effect of
angiotensin converting inhibitor treatment on glomerular hemo-
dynamic function in renal-ablated rats [28].
There have been five micropuncture studies of glomerular
hemodynamic function in rats receiving CsA [29—33]. All of the
studies utilized the Munich Wistar rat, and the dose of CsA
administered varied from 20 mg/kg i.v. [30, 33] to 30 mg/kg/day
p.o. [29, 32] to 50 mg/kg is. [311. Three of the studies limited
observations to a period immediately following the acute intrave-
nous administration of CsA [30, 31, 33], while Winston, Feingold
and Safirstein [32] treated rats for 7 to 14 days, and Thompson et
al treated rats for 8 days [29].
The decrease in SNGFR observed in these studies was uni-
formly associated with a decline in single nephron plasma flow
rate, but the effect of CsA on AP and I( was not uniform. High
dose intravenous CsA raised AP and lowered K1 in the studies by
Barros et al [31] and Sabbatini et al [30]. In contrast, Kon et al
observed a decline in AP and an increase in Kf, despite the
administration of a similar dose of CsA (20 mg/kg) [33]. Blantz
and coworkers also observed a fall in AP together with an increase
in Kf in rats that received oral CsA for 8 days [29]. We did not
observe significant differences between mean values for K1 and AP
in PLAC-SAFF rats and CsA-SAFF rats receiving 10 mg/kg/day of
CsA, but the tendency for AP to be higher and K1 to be lower in
CsA-SAFF rats is in accord with the observations by Barros et al
[31] and Sabbatini et al [30], and dietary supplementation with EP
oil lowered AP and raised K1 in CsA-EP rats.
Whole blood trough levels of CsA are similar in BHR receiving
10 mg/kg/day of CsA and standard chow supplemented with either
SAFF oil or EP oil [9], but it is possible that maintenance of
normal SNGFR in CsA-EP rats could have been due to decreased
incorporation of CsA into kidney tissue, especially since CsA is a
lipophilic compound [1], and EP alters tissue lipid composition
[10, 34]. Accordingly, a second aim of the current study was to
determine if dietary supplementation with EP oil reduced incor-
poration of CsA into kidney tissue.
As illustrated in Figure 1, tissue incorporation of 3H-CYA (a
measure of both parent compound and metabolites) into liver and
kidney tissue was similar in BHR receiving standard Purina chow
supplemented with either SAFF oil or EP oil, and these observa-
tions do not support the hypothesis that EP oil supplementation
preserves glomerular filtration rate in CsA-treated BHR by
reducing tissue incorporation of CsA in the kidney. However, the
studies do not exclude the possibility that tissue distribution of
CsA is altered when CsA is administered chronically.
Dietary supplementation with EP oil, containing 9% GLA
[18:3(n-6)], increases tissue dihomo-gamma linolenic acid (DGLA)
[20:3(n-6)] [10, 11, 14, 26]. As illustrated in Figure 3, DGLA is the
precursor for the 1-series prostanoids but it is also converted by
AS desaturase to arachidonic acid [20:4(n-6)] [12, 14], the precur-
sor for 2-series prostanoids. Thus dietary supplementation with
EP can increase tissue prostaglandin E production [11, 14}, and
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maneuver that has also been shown to attenuate CsA nephrotox-
icity [351. Fish oil contains long chain n-3 polysaturated fatty acids
which are incorporated into membrane phospholipids [361. When
released by phospholipases, n-3 fatty acids compete with arachi-
donic acid for cyclooygenase leading to the production of 3- series
prostanoids which have less biological activity [37J. Accordingly, a
final aim of the current study was to determine if dietary
supplementation with EP increased renal vasodilatory prostanoid
production in BHR.
PGE production by glomeruli increased in BHR maintained on
EP oil (Fig. 2), and it is tempting to speculate that this effect was
responsible, at least in part, for maintenance of GFR in the
CsA-EP rats. In support of this hypothesis, studies have shown
that infusion of the synthetic PGE1 analogue, misoprostil, in-
creases GFR in CsA-treated rats [38].
Clinical and experimental studies have demonstrated that renal
eicosanoid metabolism is altered by CsA treatment [1, 161. In rats,
the predominant eicosanoid produced by glomerular cells is PGE
[8, 39], but the effect of CsA on urinary PGE2 has varied greatly
[6, 401. Although in vitro studies have shown that CsA can inhibit
basal PGE2 production by mesangial cells [41, we found that
glomerular PGE production did not decline in CsA-SAFF rats.
However, the failure to see a decline in PGE production from
baseline does not preclude a role for impaired PGE production in
the pathophysiology of CsA nephrotoxicity.
In vitro, vasoactive hormones, like angiotensin II, normally
increase vasodilatory prostaglandin production by vascular
smooth muscle cells and mesangial cells so that the contractile
response to the agent is attenuated [8, 42—44]. If CsA increases
angiotensin II activity [45] or endothelin I [33, 48] in the renal
microvasculature, then the normal compensatory response of
renal vascular smooth muscle cells and mesangial cells should be
to increase vasodilatory prostaglandin production. However, stud-
ies have shown that CsA also inhibits vasoactive hormone stimu-
lated prostaglandin production by these cells so that any contrac-
tile response is enhanced [42—44]. PGE production was
unchanged in CsA-SAFF rats, despite a trend to higher values for
renal vascular resistance, suggesting that, like the in vitro experi-
ments [8, 42], the expected compensatory rise in PGE production
was blunted. Dietary supplementation with EP, containing GLA,
increased PGE production; this is an effect that could have
contributed, in part, to the maintenance of normal values for
SNGFR in the CsA-EP rats. In support of this hypothesis, studies
have shown that diets rich in GLA blunt the arterial pressor
response to acute intravenous administration of angiotensin II
[26, 27].
Studies have also shown that CsA treatment can increase
urinary TxB2 excretion, the stable metabolite of TxA2 [1, 6].
Remuzzi and coworkers have extended this observation by show-
ing that the urinary excretion of 2,3-dinor TxB2, a metabolite
thought to reflect systemic TxA2 release, is increased in CsA
treated rats along with the urinary excretion of TxB2 [47].
Thromboxane synthetase inhibition reduces urinary excretion of
TxB2 and attenuates the fall in glomerular filtration rate in CsA
treated rats [48]. TxA2 is the major eicosanoid product of platelets
[6] and it is tempting to speculate that the high doses of CsA
utilized in these studies (50mg/kg/day) damaged endothelial cells
[6, 40], leading to platelet aggregation in the glomerular micro-
circulation and subsequent local release of TxB2. Glomerular
TxB2 production does not increase in CsA-SAFF rats (unpub-
lished observation), although the rats received only 10 mg/kg/day
of CsA.
In summary, the current study establishes that dietary supple-
mentation with EP oil normalizes renal vascular resistance and
raises Kf so that SNGFR does not fall in CsA-treated BHR.
Dietary supplementation with EP oil does not lower renal tissue
levels of CsA, but does increase renal production of PGE. These
results suggest that dietary supplementation with EP oil may be a
useful means of preserving the glomerular filtration rate during
CsA treatment.
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